Drug treatment of SARS-Cov2: Potential effects in patients with substance use disorders (SUD).
作者信息
Ghosh Abhishek, Roub Fazle, Bisaga Adam
机构信息
Drug De-addiction and Treatment Centre, Department of Psychiatry Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Drug De-addiction and Treatment Centre, Department of Psychiatry Postgraduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
J Psychosom Res. 2020 Aug;135:110159. doi: 10.1016/j.jpsychores.2020.110159. Epub 2020 May 22.
Abstract
摘要
相似文献
1
Drug treatment of SARS-Cov2: Potential effects in patients with substance use disorders (SUD).
J Psychosom Res. 2020 Aug;135:110159. doi: 10.1016/j.jpsychores.2020.110159. Epub 2020 May 22.
2
Network perturbation analysis in human bronchial epithelial cells following SARS-CoV2 infection.
Exp Cell Res. 2020 Oct 15;395(2):112204. doi: 10.1016/j.yexcr.2020.112204. Epub 2020 Jul 28.
3
Coronavirus-Associated Coagulopathy: Lessons From SARS-CoV1 and MERS-CoV for the Current SARS-CoV2 Pandemic.
Cureus. 2020 Nov 3;12(11):e11310. doi: 10.7759/cureus.11310.
4
Mortality risk in post-operative head and neck cancer patients during the SARS-Cov2 pandemic: early experiences.
Eur Arch Otorhinolaryngol. 2021 Jan;278(1):275-278. doi: 10.1007/s00405-020-06138-w. Epub 2020 Jun 22.
5
Silico analysis of interaction between full-length SARS-CoV2 S protein with human Ace2 receptor: Modelling, docking, MD simulation.
Biophys Chem. 2020 Dec;267:106472. doi: 10.1016/j.bpc.2020.106472. Epub 2020 Sep 3.
6
The Progression of SARS Coronavirus 2 (SARS-CoV2): Mutation in the Receptor Binding Domain of Spike Gene.
Immune Netw. 2020 Oct 26;20(5):e41. doi: 10.4110/in.2020.20.e41. eCollection 2020 Oct.
7
GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.
Front Immunol. 2020 Jun 26;11:1638. doi: 10.3389/fimmu.2020.01638. eCollection 2020.
8
Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.
Sci Rep. 2020 Oct 19;10(1):17699. doi: 10.1038/s41598-020-74715-4.
9
Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review.
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 2;106:110070. doi: 10.1016/j.pnpbp.2020.110070. Epub 2020 Aug 12.
10
Cross-national patterns of substance use disorder treatment and associations with mental disorder comorbidity in the WHO World Mental Health Surveys.
Addiction. 2019 Aug;114(8):1446-1459. doi: 10.1111/add.14599. Epub 2019 Jun 2.
引用本文的文献
1
The effects of opium consumption on severity of disease on hospitalized COVID-19 patients in East of Iran, a prospective cohort study.
Transl Clin Pharmacol. 2024 Mar;32(1):52-62. doi: 10.12793/tcp.2024.32.e4. Epub 2024 Mar 7.
2
Drug Synergism of Anticancer Action in Combination with Favipiravir and Paclitaxel on Neuroblastoma Cells.
Medicina (Kaunas). 2023 Dec 30;60(1):82. doi: 10.3390/medicina60010082.
3
COVID-19-Related Neuropsychiatric Symptoms in Patients With Alcohol Abuse Conditions During the SARS-CoV-2 Pandemic: A Retrospective Cohort Study Using Real World Data From Electronic Health Records of a Tertiary Hospital.
Front Neurol. 2021 Mar 3;12:630566. doi: 10.3389/fneur.2021.630566. eCollection 2021.
4
Psychological factors associated with substance use initiation during the COVID-19 pandemic.
Psychiatry Res. 2020 Nov;293:113407. doi: 10.1016/j.psychres.2020.113407. Epub 2020 Aug 18.
本文引用的文献
1
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.
JHEP Rep. 2020 Jun;2(3):100113. doi: 10.1016/j.jhepr.2020.100113. Epub 2020 Apr 2.
2
Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society.
Indian Pacing Electrophysiol J. 2020 May-Jun;20(3):117-120. doi: 10.1016/j.ipej.2020.04.003. Epub 2020 Apr 8.
3
Collision of the COVID-19 and Addiction Epidemics.
Ann Intern Med. 2020 Jul 7;173(1):61-62. doi: 10.7326/M20-1212. Epub 2020 Apr 2.
4
Seizures as a rare adverse effect of chloroquine therapy in systemic lupus erythematosus patients: a case report and literature survey.
Postepy Dermatol Alergol. 2018 Aug;35(4):429-430. doi: 10.5114/ada.2018.77675. Epub 2018 Aug 21.
5
Alcoholic Myopathy: Pathophysiologic Mechanisms and Clinical Implications.
Alcohol Res. 2017;38(2):207-217.
6
Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen.
Br J Clin Pharmacol. 2015 Nov;80(5):1076-85. doi: 10.1111/bcp.12644. Epub 2015 Jun 8.
7
Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir.
Eur J Clin Pharmacol. 2010 Oct;66(10):977-85. doi: 10.1007/s00228-010-0879-1. Epub 2010 Aug 10.
8
Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.
Clin Pharmacol Ther. 2007 Jan;81(1):69-75. doi: 10.1038/sj.clpt.6100027.
9
The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.
Clin Infect Dis. 2003 Aug 15;37(4):476-82. doi: 10.1086/376907. Epub 2003 Aug 1.
10
Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment.
J Am Acad Dermatol. 2000 Jun;42(6):983-7.
Zotero 插件